Recently, the EBV BNLF2b Antibody Detection Kit (Magnetic Microparticle Chemiluminescence), jointly developed by Xiamen University and WAITAl BioPharm, has been approved for marketing by the National Medical Products Administration of China, with the registration certificate number 20243402134.

In a previous report, Professor Xia Ningshao’s team in Xiang An Biomedine Laboratory of Xiamen University, after years of scientific research, discovered the world's first serological biomarkers of nasopharyngeal cancer: the anti–BNLF2b total antibody (P85-Ab).

P85-Ab was the most promising biomarker for nasopharyngeal carcinoma screening, with high sensitivity (94.4%; 95% confidence interval [CI], 86.4 to 97.8) and specificity (99.6%; 95% CI, 97.8 to 99.9) in the retrospective case–control study. Among the 24,852 eligible participants in the prospective cohort, 47 cases of nasopharyngeal carcinoma (38 at an early stage) were identified. P85-Ab showed higher sensitivity than the two-antibody method (97.9% vs. 72.3%; ratio, 1.4 [95% CI, 1.1 to 1.6]), higher specificity (98.3% vs. 97.0%; ratio, 1.01 [95% CI, 1.01 to 1.02]), and a higher positive predictive value (10.0% vs. 4.3%; ratio, 2.3 [95% CI, 1.8 to 2.8]). The combination of P85-Ab and the two-antibody method markedly increased the positive predictive value to 44.6% (95% CI, 33.8 to 55.9), with sensitivity of 70.2% (95% CI, 56.0 to 81.4). (From Abstract)

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2301496?query=featured_home